Progress in the Treatment of Refractory Myasthenia Gravis
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
D Liu, J Mao, J Song, M Wang
Revista de Neurología, 2026
imrpress.com
Myasthenia gravis (MG) is an autoantibody-mediated, cellular immune-dependent and complement system-involved autoimmune disorder characterized by acquired neuromuscular junction transmission dysfunction driven by genetic and environmental factors. Approximately 10% therapies such as cholinesterase inhibitors, glucocorticoids, and immunosuppressants, resulting in the development of refractory MG (RMG). The current emergence of new therapeutic strategies such as targeted biologics (eg, complement …

